Zheng Quan Ri Bao·2025-10-23 19:15Core Insights - The equity market has shown strength in the first three quarters of the year, with 53 public funds achieving a net value growth rate exceeding 100%, highlighting a focus on technology and innovative pharmaceuticals [1][2] Group 1: Fund Performance - Yongying Technology Smart Mixed Fund A achieved a remarkable net value growth rate of 194.49%, leading the market, followed by Huatai-PineBridge Hong Kong Advantage Selection Mixed Fund A at 161.10% and China Europe Digital Economy Mixed Fund A at 140.86% [1] - The Longview Pharmaceutical Industry Selection A Fund also performed well, with a net value growth rate of 102.02%, ranking 45th in the market [3] Group 2: Investment Strategies - Yongying Technology Smart Mixed Fund A employed a high industry concentration strategy, focusing on the global cloud computing sector, with a stock position of 91.59% as of the end of Q3 [2] - The top three holdings of Yongying Technology Smart Mixed Fund A include Xinyi Technology, Zhongji Xuchuang, and Tianfu Communication, each with a market value exceeding 1 billion [2] Group 3: Fund Growth and Capital Inflows - The net asset value of Yongying Technology Smart Mixed Fund A surged from 1.166 billion to 11.521 billion, with shares increasing from 700 million to 3.466 billion [2] - Longview Pharmaceutical Industry Selection A Fund's size grew from 1.132 billion to 1.790 billion during the same period [3]